TIWN
Seattle, Aug 6 (TIWN) The biotechnology major Moderna which has entered the phase III clinical trials for its Covid-19 vaccine has selected Amazon Web Services (AWS) as its preferred Cloud partner as well as its standard for analytics and Machine Learning (ML) workloads.
Moderna is pioneering a new class of messenger RNA (mRNA) medicines.
Leveraging its mRNA platform and manufacturing facility with the AWS-powered research engine, Moderna delivered the first clinical batch of its vaccine candidate (mRNA-1273) against COVID-19 to the NIH for the Phase I trial, 42 days after the initial sequencing of the virus.
“The science behind mRNA medicines is advancing at a rapid pace, and building Moderna’s technology platform on AWS gives our scientists the insights, agility, and security they need to continue to lead in the industry,” said Stephane Bancel, Moderna’s Chief Executive Officer.
“With AWS, our researchers have the ability to quickly design and execute research experiments and rapidly uncover new insights to get potentially life-saving treatments into production faster,” Bancel said in a statement late on Wednesday.
Moderna has invented proprietary technologies and methods that run on AWS to create mRNA constructs that cells recognize as if they were produced in the body.
- IMF expects India to rev up global growth as China falters, backs Modi government's economic policies
- realme set to shake up market: Launching fastest entry-level 5G smartphone 'C65' under Rs 10k
- India's industrial production accelerates to 5.7pc in Feb
- India records 17 pc jump to become 4th largest exporter of digital services: WTO report
- 300 pc rise in market cap to Rs 400 lakh crore in last 10 years driven by strong economic fundamentals